CL2023001747A1 - Composición farmacéutica de agonistas duales de glp-1/glp-2 - Google Patents
Composición farmacéutica de agonistas duales de glp-1/glp-2Info
- Publication number
- CL2023001747A1 CL2023001747A1 CL2023001747A CL2023001747A CL2023001747A1 CL 2023001747 A1 CL2023001747 A1 CL 2023001747A1 CL 2023001747 A CL2023001747 A CL 2023001747A CL 2023001747 A CL2023001747 A CL 2023001747A CL 2023001747 A1 CL2023001747 A1 CL 2023001747A1
- Authority
- CL
- Chile
- Prior art keywords
- glp
- agonists
- pharmaceutical composition
- dual
- dual glp
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000003755 preservative agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20214562 | 2020-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001747A1 true CL2023001747A1 (es) | 2024-01-19 |
Family
ID=74141274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001747A CL2023001747A1 (es) | 2020-12-16 | 2023-06-14 | Composición farmacéutica de agonistas duales de glp-1/glp-2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240024425A1 (https=) |
| EP (1) | EP4262745B1 (https=) |
| JP (1) | JP7809117B2 (https=) |
| KR (1) | KR20230121823A (https=) |
| CN (1) | CN116710114B9 (https=) |
| AU (1) | AU2021404497A1 (https=) |
| CA (1) | CA3200526A1 (https=) |
| CL (1) | CL2023001747A1 (https=) |
| ES (1) | ES3019509T3 (https=) |
| IL (1) | IL301893A (https=) |
| MX (1) | MX2023006284A (https=) |
| WO (1) | WO2022129311A1 (https=) |
| ZA (1) | ZA202304235B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202111311WA (en) | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
| IL301892A (en) * | 2020-12-16 | 2023-06-01 | Zealand Pharma As | Drug composition of dual GLP-1/GLP-2 agonists |
| JP2024533153A (ja) * | 2021-09-03 | 2024-09-12 | ジーランド ファーマ エー／エス | 投薬レジーム |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| MXPA04003569A (es) * | 2001-10-19 | 2004-07-23 | Lilly Co Eli | Mezclas bifasicas de glp-1 e insulina. |
| ES2373660T3 (es) | 2003-11-13 | 2012-02-07 | Novo Nordisk A/S | Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo. |
| CN104902922B (zh) * | 2012-11-13 | 2017-12-12 | 阿道恰公司 | 包含经取代阴离子化合物的速效胰岛素制剂 |
| CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| EP3551651B1 (en) * | 2016-12-09 | 2024-03-06 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
| SG11202111311WA (en) * | 2019-06-14 | 2021-12-30 | Zealand Pharma As | Pharmaceutical parenteral composition of dual glp1/2 agonist |
-
2021
- 2021-12-16 CA CA3200526A patent/CA3200526A1/en active Pending
- 2021-12-16 JP JP2023536095A patent/JP7809117B2/ja active Active
- 2021-12-16 US US18/039,857 patent/US20240024425A1/en active Pending
- 2021-12-16 MX MX2023006284A patent/MX2023006284A/es unknown
- 2021-12-16 WO PCT/EP2021/086147 patent/WO2022129311A1/en not_active Ceased
- 2021-12-16 CN CN202180080845.4A patent/CN116710114B9/zh active Active
- 2021-12-16 ES ES21836185T patent/ES3019509T3/es active Active
- 2021-12-16 IL IL301893A patent/IL301893A/en unknown
- 2021-12-16 KR KR1020237023812A patent/KR20230121823A/ko active Pending
- 2021-12-16 EP EP21836185.5A patent/EP4262745B1/en active Active
- 2021-12-16 AU AU2021404497A patent/AU2021404497A1/en active Pending
-
2023
- 2023-04-06 ZA ZA2023/04235A patent/ZA202304235B/en unknown
- 2023-06-14 CL CL2023001747A patent/CL2023001747A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7809117B2 (ja) | 2026-01-30 |
| ES3019509T3 (en) | 2025-05-20 |
| IL301893A (en) | 2023-06-01 |
| CN116710114B (zh) | 2025-11-25 |
| CA3200526A1 (en) | 2022-06-23 |
| MX2023006284A (es) | 2023-06-13 |
| US20240024425A1 (en) | 2024-01-25 |
| EP4262745C0 (en) | 2025-01-29 |
| ZA202304235B (en) | 2025-08-27 |
| JP2023553561A (ja) | 2023-12-22 |
| KR20230121823A (ko) | 2023-08-21 |
| TW202228764A (zh) | 2022-08-01 |
| WO2022129311A1 (en) | 2022-06-23 |
| EP4262745B1 (en) | 2025-01-29 |
| AU2021404497A1 (en) | 2023-06-08 |
| CN116710114A (zh) | 2023-09-05 |
| EP4262745A1 (en) | 2023-10-25 |
| CN116710114B9 (zh) | 2026-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001747A1 (es) | Composición farmacéutica de agonistas duales de glp-1/glp-2 | |
| CL2023001745A1 (es) | Composición farmacéutica de agonistas duales de glp-1/glp-2 | |
| MX2023006281A (es) | Composicion farmaceutica de agonistas duales de glp-1/glp-2. | |
| CL2021001430A1 (es) | Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422) | |
| CO2022011728A2 (es) | Composiciones y usos de glp-1 | |
| BR112017018276A2 (pt) | ?composição que compreende peptidase e biotensoativo e seu uso? | |
| MX2020006612A (es) | Compuesto que funciona como inhibidor de proteína de bromodominio y composición. | |
| CL2021003272A1 (es) | Composición farmacéutica parenteral del agonista dual glp1/2 | |
| BR112015023387A2 (pt) | composições lipídicas de racecodotril | |
| MX2019000902A (es) | Desinfectantes topicos emolientes. | |
| MX2022006903A (es) | Productos orales con irritacion reducida. | |
| MX2019001121A (es) | Nuevas formulaciones y composiciones de cannabis en comprimidos y metodos para su elaboracion. | |
| SA519402556B1 (ar) | تركيبات تجميلية للعناية بالبشرة. | |
| BR112015022520A2 (pt) | composições de ligante e métodos para produzir e usar as mesmas | |
| CO6321288A2 (es) | Sales de compuestos inhibidores de vih | |
| CL2019002516A1 (es) | Composiciones cosméticas para el cuidado de la piel. | |
| BR112023001471A2 (pt) | Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma | |
| CL2021002838A1 (es) | Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo. | |
| MX2022006320A (es) | Composicion para la inhibicion de la produccion de hmf que comprende disacarido de alulosa. | |
| CO2023000239A2 (es) | Excipientes reductores de viscosidad y combinaciones de los mismos para formulaciones de proteína altamente concentradas | |
| ECSP22040362A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| DOP2010000088A (es) | Compuesto inhibidor de fosforilasa de glicógeno y composición farmacéutica del mismo. | |
| MX388400B (es) | Una composición de dos componentes, que comprende ácido acetilsalicílico. | |
| MX2022003398A (es) | Composicion micelar inmunoestimulante. | |
| CL2021002097A1 (es) | Uso de triglicéridos caprílicos y cápricos para el tratamiento de una enfermedad o afección mediada por una deficiencia de filagrina o colágeno. |